Welcome to our dedicated page for International Stem Cell SEC filings (Ticker: ISCO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
International Stem Cell Corporation filings document governance, capital structure and material-event disclosures for a clinical-stage biotechnology issuer. Proxy materials cover annual meeting matters, director elections, executive compensation and equity-award information, including voting mechanics involving preferred stock.
Form 8-K reports record stockholder voting results and material definitive agreements, including related-party debt arrangements with a senior executive. The filings also identify the company's registered-security status under Section 12(b) and provide formal disclosures tied to its public-company governance and financing structure.
International Stem Cell Corporation reported that it has amended a loan agreement with its Co-Chairman and Chief Executive Officer, Dr. Andrey Semechkin. The company and Dr. Semechkin agreed to extend the maturity date of a $2,500,000 loan, originally documented in a promissory note dated September 15, 2024, so that the loan is now due on September 15, 2026 instead of the prior 2025 maturity.
The outstanding principal under the note continues to accrue interest at an annual rate of 5.5%, and the company may prepay the note at any time without penalty. The amended note was issued on September 15, 2025, and a form of the note is included as Exhibit 10.1, providing the detailed terms of this insider financing arrangement.